MAI Capital Management Has $566,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• MAI Capital Management has significantly reduced its stake in Regeneron Pharmaceuticals by 72.2%, leaving it with only 893 shares valued at approximately $566,000.
• Several hedge funds have recently adjusted their positions, with Brighton Jones LLC increasing its holdings by 261.8% to own 948 shares valued at $675,000.
• Regeneron Pharmaceuticals reported $12.89 EPS for the quarter, surpassing expectations, and declared a quarterly dividend of $0.88, contributing to an annual yield of 0.6%.

MAI Capital Management cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 72.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 893 shares of the biopharmaceutical company's stock after selling 2,318 shares during the quarter. MAI Capital Management's holdings in Regeneron Pharmaceuticals were worth $566,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $27,000. Finally, Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $27,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $761.00 price target (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Finally, Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $0.70 during trading hours on Wednesday, hitting $555.83. The company had a trading volume of 874,662 shares, compared to its average volume of 959,295. The firm has a 50-day moving average of $563.85 and a 200 day moving average of $581.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market cap of $58.91 billion, a PE ratio of 14.01, a PEG ratio of 1.86 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.56 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.